Investing.com -- Boston Scientific (NYSE:BSX) stock climbed over 1% in premarket trading Wednesday after the company raised its full-year earnings guidance, surpassing the consensus estimate.

Boston Scientific BSX has outperformed the market over the past 10 years by 10.35% on an annualized basis producing an average annual return of 22.01%. Currently, Boston Scientific has a market ...

Boston Scientific reported Q3 revenue of $4.21 billion, beating estimates. EPS reached $0.63, surpassing consensus of $0.59. Cardiovascular sales rose 25%, and MedSurg increased 10.3% ...

See our leaderboard of companies with the largest price target upside. The projected annual revenue for Boston Scientific is ...

On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial ...

To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common ... "General Methodology and Use of Estimated Annual Effective Tax Rate." ...

Boston Scientific reported 29.2% growth for cardiology products and 11.8% growth in peripheral interventions. MedSurg segment revenues increased 10.3% to $1.48 billion (10.4% operationally and 7.7 ...